Skip to content

Alumis Inc. ALMS Earnings yield

Earnings yield at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
5.9%+1.6pp
Amgen logo
AmgenAMGN
4.1%+0.6pp
Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
-4.8%-2.2pp
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
5.3%+4.4pp
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
-13.4%-1.2pp
Immunome logo
ImmunomeIMNM
-9.1%-3.9pp

Other financials

Income statement

See full
Revenue$1.7M-90.0%
Operating income-$98.4M+3.1%
Net income-$93.1M+6.0%
EPS (diluted)-$0.74+59.3%

Balance sheet

See full
Cash & equivalents$63.9M-50.3%
Total debt$35.7M+1,881%
Total equity$567.0M+237%
Total assets$671.6M+157%

Cash flow

See full
Operating cash flow-$87.1M-8.4%
CapEx$164.0K+343%
Free cash flow-$87.2M-8.5%

Valuation

See full
Market cap$3.12B+739%
Enterprise value$3.1B+1,238%
P/S371.9×

Profitability

See full
Operating margin-5,364%
Net margin-2,825.7%
FCF margin-4,487.4%

Returns & leverage

See full
Return on equity-64.6%
Debt / equity0.1×+0.1×
Current ratio7.5×+3.8×

Where this comes from

Calculated from Alumis Inc.’s reported figures.

Based on trailing twelve months.

The official record: Alumis Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alumis Inc.'s earnings yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Alumis Inc.'s earnings yield?
Alumis Inc. (ALMS) reported earnings yield of -8.5% in Q1 2026.
How has Alumis Inc.'s earnings yield changed year-over-year?
Alumis Inc.'s earnings yield increased by 91.8% year-over-year, from -102.8% to -8.5%.
What does earnings yield mean?
Trailing-twelve-month net income divided by market capitalization at the quarter end — the inverse of the P/E ratio, expressed as a percentage.